Q4-FY26 · Krishna Kimi
We continue to believe that our growth will be led by pharma driven by increasing outsourcing intensity, movement of biotech assets into pharma pipelines and strategic long-term partnerships.
SAILIFE / language trends
Read confidence between the lines.
Sai Life Sciences · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Shiva
Our approach to capex remains science-led rather than capacity heavy, ensuring flexibility and higher long-term returns.
Q4-FY26 · Krishna Kimi
The important part of being a CR and RP is to be a fast follower, be close enough to be able to change the trend but not be on the bleeding edge where you left with the dead investment.